PharmaShots | Incisive News in 3 Shots

Subscribe Now

non-Hodgkin lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

November 19, 2021

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

October 15, 2021

$Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma$

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

May 20, 2021

Innovent and Eli Lilly Report NMPA's Acceptance of NDA for IBI301 (rituximab- biosimilar) for Non-Hodgkin's lymphoma

Innovent and Eli Lilly Report NMPA's Acceptance of NDA for IBI301 (rituximab- biosimilar) for Non-Hodgkin's lymphoma

June 28, 2019

FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

August 8, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us